Know more about

Invited Speaker: Dr. Mehdi Hasani Sadrabadi

Invited Speaker: Dr. Mehdi Hasani Sadrabadi

Invited Speaker: Dr. Mehdi Hasani Sadrabadi

T‐cell immunotherapy is a promising approach for cancer, infection, and autoimmune diseases. Deaths from solid tumors outnumber deaths from hematopoietic cancers. Yet progress in immunotherapies for solid tumors is well behind those for hematopoietic cancers. I will discuss various bioengineering strategies to improve ex vivo and in vivo immunotherapies for solid tumors by utilizing next generation biomaterials and drug delivery systems. In this talk, I will discuss our approaches on how to design biomaterials with various form factors from nano and microparticles to hydrogels and scaffolds in order to augment T-cell response to improve cancer immunotherapies. I am going to discuss antitumor response in several tumor models in mice and describe the path toward human clinical trials.